Since Dabrafenib is a clinically used agent for Ep‐GBM patients with the BRAF V600E mutation, we further investigated whether NU7441 treatment enhanced the anti‐tumor efficiency of Dabrafenib toward Ep‐GBM‐like tumors. The gene discussed is BRAF; the disease is neoplasm.